(NASDAQ: VCEL) Vericel's forecast annual revenue growth rate of 21.63% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 117.27%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 22.74%.
Vericel's revenue in 2025 is $258,717,000.On average, 10 Wall Street analysts forecast VCEL's revenue for 2026 to be $16,763,266,658, with the lowest VCEL revenue forecast at $15,870,129,359, and the highest VCEL revenue forecast at $17,514,796,684. On average, 10 Wall Street analysts forecast VCEL's revenue for 2027 to be $19,998,487,101, with the lowest VCEL revenue forecast at $18,382,646,970, and the highest VCEL revenue forecast at $21,273,964,037.
In 2028, VCEL is forecast to generate $23,647,403,077 in revenue, with the lowest revenue forecast at $22,020,942,401 and the highest revenue forecast at $24,852,582,117.